Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes -Topline data from the Phase II study for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results